Synonyms: LCQ-908 | LCQ908
Compound class:
Synthetic organic
Comment: Pradigastat is a potent and selective inhibitor of diacylglycerol O-acyltransferase 1 (DGAT1).
The PubChem CID 53387035 shows the molecule with no stereochemistry. |
|
No information available. |
Summary of Clinical Use ![]() |
Pradigastat has been granted orphan designation by the EMA (in 2012) and US FDA, for the treatment of familial chylomicronaemia syndrome (type-I hyperlipoproteinaemia). Pradigastat (under research code LCQ908) has completed a Phase 2 clinical trial for type 2 diabetes (NCT00901979). A Phase 2 trial for coronary artery disease associated with hypertriglyceridemia is recruiting patients (NCT01474434), as is a Phase 2I trial for familial chylomicronemia syndrome (NCT01589237) (as of Nov 2014). |